– Early Data Show that IPI-145 Is Well Tolerated and Has Activity in a Broad Range of B-Cell and T-Cell Lymphomas, with a 68 Percent Response Rate in Indolent Non-Hodgkin Lymphoma –
– Rapid Onset of Clinical Activity Observed, with a Median Time to Response of 1.8 Months –
CHICAGO, IL, USA I June 3, 2013 I Infinity Pharmaceuticals, Inc. (INFI) today announced updated Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with relapsed/refractory lymphoma, a group of potentially fatal hematologic malignancies, or blood cancers. Data from the study showed that IPI-145 was well tolerated and clinically active in patients with B-cell or T-cell lymphomas, including indolent non-Hodgkin lymphoma (iNHL), T-cell lymphoma, mantle cell lymphoma (MCL) and Hodgkin lymphoma (HL). These findings were presented today at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.
“I’m encouraged by the early data seen in this Phase 1 study of IPI-145. So far, IPI-145 appears to be well tolerated, with responses seen across a broad range of B-cell and T-cell lymphomas,” commented Steven Horwitz, M.D., assistant attending physician, department of medicine, Memorial Sloan-Kettering Cancer Center, and an investigator for this trial. “Many hematologic malignancies are difficult to treat and new agents are clearly needed. Targeted therapies, including IPI-145, have the potential not only to add therapeutic options for our patients but also to reduce or delay the need for chemotherapy, possibly changing the way many of these malignancies are treated.”
Infinity today also announced that its first Phase 2 study of IPI-145 in hematologic malignancies, which is enabled by data from the Phase 1 trial, is open for enrollment. This Phase 2, open-label, single-arm study is designed to evaluate the safety and efficacy of IPI-145 dosed at 25 mg twice daily (BID) in approximately 120 patients with refractory iNHL. In the Phase 1 study, among the 19 patients with iNHL evaluable for activity, 13 patients (68 percent) responded, with three complete responses and 10 partial responses. The majority of patients who responded were treated at doses ≤ 25 mg BID.
“Infinity is pleased to begin its first Phase 2 study of IPI-145 in patients with indolent non-Hodgkin lymphoma, which is supported by the early, encouraging, data from our ongoing Phase 1 study reported today at ASCO,” stated Julian Adams, Ph.D., president of research and development at Infinity. “Infinity believes IPI-145 has the potential to be the best-in-class PI3K inhibitor for the treatment of blood cancers, and we are rapidly advancing IPI-145 in the clinic with a goal of addressing significant medical needs.”
IPI-145 Data Presented at ASCO in Patients with Lymphoma
The presentation, “Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide -3-kinase-δ,γ, in patients with relapsed/refractory lymphoma” (Abstract #8518), includes 117 patients in the total safety population, of which 68 patients with lymphoma were evaluable for safety and 47 were evaluable for clinical activity.1 All patients enrolled in the study had advanced disease and had progressed during or were refractory to, intolerant of, or ineligible for established therapy. Lymphoma patients enrolled in the study had a median of four prior systemic therapies (range:one to 13), and 46 (68 percent of) patients had at least three prior systemic therapies.
Safety and Pharmacokinetics
Data presented today showed that IPI-145 was well tolerated, with a safety profile consistent with co-morbidities seen in patients with advanced hematologic malignancies. There have been no dose-related trends in adverse events at the doses evaluated, from 8 mg BID to 75 mg BID, in the total safety population or in patients with lymphoma. Among the 68 lymphoma patients enrolled in this study, the most frequent adverse event was elevation in transaminases (ALT/AST), which occurred in 21 patients (31 percent overall; 18 percent Grade 3 and one percent Grade 4). The majority of transaminase elevations were primarily managed by dose interruptions and dose reductions. Two (three percent of) patients discontinued treatment due to ALT/AST elevations. Fifty-three percent of lymphoma patients remain on study.
Data also showed that IPI-145 is rapidly absorbed and demonstrates a linear pharmacokinetic (PK) profile through 75 mg BID, with complete inhibition of PI3K-delta and at least 50 percent inhibition of PI3K-gamma at doses ≥ 25 mg BID.
Clinical Activity
IPI-145 showed clinical activity across a broad range of patients with lymphomas, with responses observed in patients with iNHL, T-cell lymphoma, MCL and HL. The onset of activity was rapid, with a median time to response of under two months (range: 1.7 – 1.9). Clinical responses in patients with lymphoma were as follows:
| |
|
|
|
|
|
|
|
|
|
| Diagnosis |
|
|
Patients (n) |
|
|
Best Observed Response (n) |
|
|
Median Time to
Response in
Months (Range)
|
| |
|
Treated |
|
|
Evaluable |
|
|
Complete
Response
|
|
|
Partial
Response
|
|
|
Stable
Disease
|
|
|
Progressive
Disease
|
|
|
| iNHL |
|
|
26 |
|
|
19 |
|
|
3 |
|
|
10 |
|
|
4 |
|
|
2 |
|
|
1.8 (1.7 – 4.1) |
| T-cell lymphoma |
|
|
17 |
|
|
9 |
|
|
1 |
|
|
2 |
|
|
2 |
|
|
4 |
|
|
1.9 (1.7 – 2.7) |
| MCL |
|
|
9 |
|
|
6 |
|
|
1 |
|
|
3 |
|
|
1 |
|
|
1 |
|
|
1.8 (1.6 – 1.9) |
| HL |
|
|
3 |
|
|
3 |
|
|
1 |
|
|
0 |
|
|
1 |
|
|
1 |
|
|
1.7 (NA) |
| aNHL* |
|
|
13 |
|
|
10 |
|
|
0 |
|
|
0 |
|
|
4 |
|
|
6 |
|
|
(NA) |
|
NA (not applicable)
|
|
*aNHL (aggressive non-Hodgkin lymphoma)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
These data were presented in McCormick Place, E354a, in Chicago, Illinois, and may also be found in the Publications Archive on Infinity’s website http://www.infi.com/product-candidates-publications.asp.
Phase 2 Trial in iNHL
A Phase 2 study of IPI-145 in iNHL is now open for enrollment. This Phase 2, multi-center, open-label, single-arm study is designed to evaluate the safety and efficacy of IPI-145 dosed at 25 mg BID in approximately 120 patients with iNHL (follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma) whose disease is refractory to combined rituximab and chemotherapy or radioimmunotherapy. The primary endpoint of the study is response rate according to the international working group criteria.2
About the Phase 1 Trial of IPI-145 in Advanced Hematologic Malignancies
The Phase 1, open-label, dose-escalation trial of IPI-145 is designed to evaluate the safety, PK and clinical activity of IPI-145 administered orally BID in patients with advanced hematologic malignancies. The dose-escalation portion of the study is complete, with the maximum tolerated dose defined at 75 mg BID. Infinity is continuing to evaluate IPI-145 in the following seven expansion cohorts:
|
25mg BID expansion cohorts
|
|
1.
|
|
Relapsed/refractory CLL, iNHL and MCL |
|
2.
|
|
Treatment-naïve CLL in high-risk patients (over age 65 or having a 17p deletion or p53 mutations) |
| |
|
75mg BID expansion cohorts
|
|
1.
|
|
Relapsed/refractory CLL, iNHL and MCL |
|
2.
|
|
T-cell lymphomas |
|
3.
|
|
Aggressive B-cell lymphomas |
|
4.
|
|
Myeloid neoplasms |
|
5.
|
|
Acute lymphoblastic leukemia |
About Infinity’s PI3K Program in Blood Cancers
Infinity is developing IPI-145, a potent, oral inhibitor of Class I phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity.3 The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in leukocytes (white blood cells), where they have distinct and mostly non-overlapping roles in immune cell development and function. Targeting PI3K-delta and PI3K-gamma may provide multiple opportunities to develop differentiated therapies for the treatment of hematologic malignancies and inflammatory diseases.
IPI-145, Infinity’s lead product candidate, is currently progressing in a Phase 2 study in patients with indolent non-Hodgkin lymphoma (iNHL) and in a Phase 1 study in patients with advanced hematologic malignancies. An investigator-sponsored Phase 1b, open-label, dose-escalation study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combination with rituximab (a monoclonal antibody therapy), bendamustine (a chemotherapy) or both rituximab and bendamustine is also open for enrollment.
Additionally, Infinity is conducting preclinical studies of IPI-443, its second oral PI3K-delta and PI3K-gamma inhibitor. IPI-443 has a distinct biochemical profile from IPI-145 and also has the potential to treat hematologic malignancies and inflammatory diseases.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity’s programs focused on the inhibition of phosphoinositide-3-kinase and heat shock protein 90 are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the company’s website at www.infi.com.
SOURCE: Infinity Pharmaceuticals
Post Views: 163
– Early Data Show that IPI-145 Is Well Tolerated and Has Activity in a Broad Range of B-Cell and T-Cell Lymphomas, with a 68 Percent Response Rate in Indolent Non-Hodgkin Lymphoma –
– Rapid Onset of Clinical Activity Observed, with a Median Time to Response of 1.8 Months –
CHICAGO, IL, USA I June 3, 2013 I Infinity Pharmaceuticals, Inc. (INFI) today announced updated Phase 1 data from an ongoing study of IPI-145, its potent, oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma in patients with relapsed/refractory lymphoma, a group of potentially fatal hematologic malignancies, or blood cancers. Data from the study showed that IPI-145 was well tolerated and clinically active in patients with B-cell or T-cell lymphomas, including indolent non-Hodgkin lymphoma (iNHL), T-cell lymphoma, mantle cell lymphoma (MCL) and Hodgkin lymphoma (HL). These findings were presented today at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.
“I’m encouraged by the early data seen in this Phase 1 study of IPI-145. So far, IPI-145 appears to be well tolerated, with responses seen across a broad range of B-cell and T-cell lymphomas,” commented Steven Horwitz, M.D., assistant attending physician, department of medicine, Memorial Sloan-Kettering Cancer Center, and an investigator for this trial. “Many hematologic malignancies are difficult to treat and new agents are clearly needed. Targeted therapies, including IPI-145, have the potential not only to add therapeutic options for our patients but also to reduce or delay the need for chemotherapy, possibly changing the way many of these malignancies are treated.”
Infinity today also announced that its first Phase 2 study of IPI-145 in hematologic malignancies, which is enabled by data from the Phase 1 trial, is open for enrollment. This Phase 2, open-label, single-arm study is designed to evaluate the safety and efficacy of IPI-145 dosed at 25 mg twice daily (BID) in approximately 120 patients with refractory iNHL. In the Phase 1 study, among the 19 patients with iNHL evaluable for activity, 13 patients (68 percent) responded, with three complete responses and 10 partial responses. The majority of patients who responded were treated at doses ≤ 25 mg BID.
“Infinity is pleased to begin its first Phase 2 study of IPI-145 in patients with indolent non-Hodgkin lymphoma, which is supported by the early, encouraging, data from our ongoing Phase 1 study reported today at ASCO,” stated Julian Adams, Ph.D., president of research and development at Infinity. “Infinity believes IPI-145 has the potential to be the best-in-class PI3K inhibitor for the treatment of blood cancers, and we are rapidly advancing IPI-145 in the clinic with a goal of addressing significant medical needs.”
IPI-145 Data Presented at ASCO in Patients with Lymphoma
The presentation, “Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide -3-kinase-δ,γ, in patients with relapsed/refractory lymphoma” (Abstract #8518), includes 117 patients in the total safety population, of which 68 patients with lymphoma were evaluable for safety and 47 were evaluable for clinical activity.1 All patients enrolled in the study had advanced disease and had progressed during or were refractory to, intolerant of, or ineligible for established therapy. Lymphoma patients enrolled in the study had a median of four prior systemic therapies (range:one to 13), and 46 (68 percent of) patients had at least three prior systemic therapies.
Safety and Pharmacokinetics
Data presented today showed that IPI-145 was well tolerated, with a safety profile consistent with co-morbidities seen in patients with advanced hematologic malignancies. There have been no dose-related trends in adverse events at the doses evaluated, from 8 mg BID to 75 mg BID, in the total safety population or in patients with lymphoma. Among the 68 lymphoma patients enrolled in this study, the most frequent adverse event was elevation in transaminases (ALT/AST), which occurred in 21 patients (31 percent overall; 18 percent Grade 3 and one percent Grade 4). The majority of transaminase elevations were primarily managed by dose interruptions and dose reductions. Two (three percent of) patients discontinued treatment due to ALT/AST elevations. Fifty-three percent of lymphoma patients remain on study.
Data also showed that IPI-145 is rapidly absorbed and demonstrates a linear pharmacokinetic (PK) profile through 75 mg BID, with complete inhibition of PI3K-delta and at least 50 percent inhibition of PI3K-gamma at doses ≥ 25 mg BID.
Clinical Activity
IPI-145 showed clinical activity across a broad range of patients with lymphomas, with responses observed in patients with iNHL, T-cell lymphoma, MCL and HL. The onset of activity was rapid, with a median time to response of under two months (range: 1.7 – 1.9). Clinical responses in patients with lymphoma were as follows:
| |
|
|
|
|
|
|
|
|
|
| Diagnosis |
|
|
Patients (n) |
|
|
Best Observed Response (n) |
|
|
Median Time to
Response in
Months (Range)
|
| |
|
Treated |
|
|
Evaluable |
|
|
Complete
Response
|
|
|
Partial
Response
|
|
|
Stable
Disease
|
|
|
Progressive
Disease
|
|
|
| iNHL |
|
|
26 |
|
|
19 |
|
|
3 |
|
|
10 |
|
|
4 |
|
|
2 |
|
|
1.8 (1.7 – 4.1) |
| T-cell lymphoma |
|
|
17 |
|
|
9 |
|
|
1 |
|
|
2 |
|
|
2 |
|
|
4 |
|
|
1.9 (1.7 – 2.7) |
| MCL |
|
|
9 |
|
|
6 |
|
|
1 |
|
|
3 |
|
|
1 |
|
|
1 |
|
|
1.8 (1.6 – 1.9) |
| HL |
|
|
3 |
|
|
3 |
|
|
1 |
|
|
0 |
|
|
1 |
|
|
1 |
|
|
1.7 (NA) |
| aNHL* |
|
|
13 |
|
|
10 |
|
|
0 |
|
|
0 |
|
|
4 |
|
|
6 |
|
|
(NA) |
|
NA (not applicable)
|
|
*aNHL (aggressive non-Hodgkin lymphoma)
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
These data were presented in McCormick Place, E354a, in Chicago, Illinois, and may also be found in the Publications Archive on Infinity’s website http://www.infi.com/product-candidates-publications.asp.
Phase 2 Trial in iNHL
A Phase 2 study of IPI-145 in iNHL is now open for enrollment. This Phase 2, multi-center, open-label, single-arm study is designed to evaluate the safety and efficacy of IPI-145 dosed at 25 mg BID in approximately 120 patients with iNHL (follicular lymphoma, marginal zone lymphoma, small lymphocytic lymphoma) whose disease is refractory to combined rituximab and chemotherapy or radioimmunotherapy. The primary endpoint of the study is response rate according to the international working group criteria.2
About the Phase 1 Trial of IPI-145 in Advanced Hematologic Malignancies
The Phase 1, open-label, dose-escalation trial of IPI-145 is designed to evaluate the safety, PK and clinical activity of IPI-145 administered orally BID in patients with advanced hematologic malignancies. The dose-escalation portion of the study is complete, with the maximum tolerated dose defined at 75 mg BID. Infinity is continuing to evaluate IPI-145 in the following seven expansion cohorts:
|
25mg BID expansion cohorts
|
|
1.
|
|
Relapsed/refractory CLL, iNHL and MCL |
|
2.
|
|
Treatment-naïve CLL in high-risk patients (over age 65 or having a 17p deletion or p53 mutations) |
| |
|
75mg BID expansion cohorts
|
|
1.
|
|
Relapsed/refractory CLL, iNHL and MCL |
|
2.
|
|
T-cell lymphomas |
|
3.
|
|
Aggressive B-cell lymphomas |
|
4.
|
|
Myeloid neoplasms |
|
5.
|
|
Acute lymphoblastic leukemia |
About Infinity’s PI3K Program in Blood Cancers
Infinity is developing IPI-145, a potent, oral inhibitor of Class I phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma. The PI3Ks are a family of enzymes involved in multiple cellular functions, including cell proliferation and survival, cell differentiation, cell migration and immunity.3 The PI3K-delta and PI3K-gamma isoforms are preferentially expressed in leukocytes (white blood cells), where they have distinct and mostly non-overlapping roles in immune cell development and function. Targeting PI3K-delta and PI3K-gamma may provide multiple opportunities to develop differentiated therapies for the treatment of hematologic malignancies and inflammatory diseases.
IPI-145, Infinity’s lead product candidate, is currently progressing in a Phase 2 study in patients with indolent non-Hodgkin lymphoma (iNHL) and in a Phase 1 study in patients with advanced hematologic malignancies. An investigator-sponsored Phase 1b, open-label, dose-escalation study of IPI-145 in patients with B-cell NHL, CLL and T-cell lymphoma in combination with rituximab (a monoclonal antibody therapy), bendamustine (a chemotherapy) or both rituximab and bendamustine is also open for enrollment.
Additionally, Infinity is conducting preclinical studies of IPI-443, its second oral PI3K-delta and PI3K-gamma inhibitor. IPI-443 has a distinct biochemical profile from IPI-145 and also has the potential to treat hematologic malignancies and inflammatory diseases.
About Infinity Pharmaceuticals, Inc.
Infinity is an innovative biopharmaceutical company dedicated to discovering, developing and delivering best-in-class medicines to people with difficult-to-treat diseases. Infinity combines proven scientific expertise with a passion for developing novel small molecule drugs that target emerging disease pathways. Infinity’s programs focused on the inhibition of phosphoinositide-3-kinase and heat shock protein 90 are evidence of its innovative approach to drug discovery and development. For more information on Infinity, please refer to the company’s website at www.infi.com.
SOURCE: Infinity Pharmaceuticals
Post Views: 163
